A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer

NCT03663205 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

334

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Tislelizumab
DRUG: Cisplatin
DRUG: Carboplatin
DRUG: Pemetrexed

Sponsor

BeiGene